Diabetes Ther Res Treat Educ Diabetes Relat Disord 9(5):19952014
Key Takeaways Two biotech companies, Akston Biosciences and OKAVA Pharmaceuticals, are running early trials of once-weekly injections and a six-month implant GLP-1 treatment to tackle feline obesity, with no approved Ozempic for pets on the market yet
Fiber and Gut Health Support Some GLP-1 users experience constipation, while others may experience diarrhea or general digestive discomfort
Beginning July 1 and running through the end of 2027, a new pilot program will allow some Medicare Part D prescription plan members who want to shed excess pounds and maintain weight loss to get Wegovy injections and tablets, Foundayo tablets or the Zepbound KwikPen for a $50 monthly copay
Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy
The role of high-fat meals on pharmacokinetic behaviour is also relevant